No matter which production route you choose, BayMedica can scale cannabinoid ingredient supply to meet your growing demand. Our infrastructure and quality systems support consistent, large-volume production with the same purity, documentation, and reliability for each batch produced. This ensures your brand can expand confidently, knowing your cannabinoid ingredients will scale with you.

BayMedica’s platform-agnostic model is built to help you stay compliant as regulations evolve. Whether your markets require plant-derived, semi-synthesized, or fully synthesized cannabinoids, we offer consistent, reproducible options that align with evolving standards worldwide. This flexibility ensures your ingredient supply remains uninterrupted and your products stay ready for what’s next.

BayMedica operates within a food-grade quality framework designed to meet industry norms. Every step, from sourcing to large-scale production, is governed by strict documentation, verification, and testing protocols that ensure consistency and reproducibility. For product developers, this means dependable ingredients, trusted data, and confidence that your formulations will perform the same every time.

BayMedica maintains batch traceability through to the finished product. For plant-derived products, this includes chain of custody documentation. Each step in production and handling is documented and linked to batch-specific data, ensuring full traceability and accountability. For brands and quality teams, this provides transparency, audit readiness, and confidence that every batch originates from a controlled, compliant source.

Each BayMedica ingredient is known from initial production through final release, supported by MSDS and specification sheets, attestations, and other documentation, with the final batch tested by two third-party labs, which then provide two independent third-party Certificates of Analysis. This documentation ensures visibility, accountability, and quality for every batch. For your team, it means complete confidence in ingredient integrity and readiness for regulatory or customer audits.

BayMedica’s cannabinoids are produced under food-grade GMP standards designed to meet the expectations of global CPG and nutraceutical brands. Every batch is manufactured, tested, and documented within controlled environments that prioritize safety, reproducibility, and compliance. For your team, this means ingredient quality you can trust and a supply partner ready for mainstream regulatory adoption.

All BayMedica cannabinoid products are verified non-intoxicating, and testing includes detection of THC to confirm non-detectable levels, with the exception of select formulations such as THCV from hemp, where trace THC content is verified to be less than regulatory specifications. This level of purity ensures compliance and provides brands with peace of mind when formulating for regulated or THC-restricted markets.

BayMedica’s D9-THCV is highly purified, and each batch is tested internally and by two third parties. Typical D8-THCV content in BayMedica’s D9-THCV is at or below 3%. When used at normal formulation levels, trace D8-THCV levels are expected to dilute below detection in most finished product matrices. This supports purity, compliance, and batch-to-batch consistency to meet your internal quality ND D8-THCV targets and evolving expectations from regulators and retail partners.

BayMedica has conducted controlled stability testing on THCV to verify its integrity over time and across formulation conditions. This data helps brands and formulators understand how the compound behaves in real-world applications, supporting more reliable shelf-life and performance. This additional stability assurance gives BayMedica partners a measurable advantage in product development and quality assurance. Read more about THCV and oxidation here.